Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV.
Jessica J WyseKathleen A McGinnisE Jennifer EdelmanAdam J GordonAjay ManhapraDavid A FiellinBrent A MooreP Todd KorthuisAmy J KennedyBenjamin J OldfieldJulie R GaitherKirsha S GordonMelissa SkandersonDeclan T BarryKendall BryantStephen CrystalAmy C JusticeKevin L KraemerPublished in: AIDS and behavior (2021)
Although opioid agonist therapy (OAT) is associated with positive health outcomes, including improved HIV management, long-term retention in OAT remains low among patients with opioid use disorder (OUD). Using data from the Veterans Aging Cohort Study (VACS), we identify variables independently associated with OAT retention overall and by HIV status. Among 7,334 patients with OUD, 13.7% initiated OAT, and 27.8% were retained 12-months later. Likelihood of initiation and retention did not vary by HIV status. Variables associated with improved likelihood of retention included receiving buprenorphine (relative to methadone), receiving both buprenorphine and methadone at some point over the 12-month period, or diagnosis of HCV. History of homelessness was associated with a lower likelihood of retention. Predictors of retention were largely distinct between patients with HIV and patients without HIV. Findings highlight the need for clinical, systems, and research initiatives to better understand and improve OAT retention.
Keyphrases
- antiretroviral therapy
- hiv positive
- hiv infected
- human immunodeficiency virus
- hiv testing
- hepatitis c virus
- hiv aids
- men who have sex with men
- south africa
- chronic pain
- end stage renal disease
- pain management
- newly diagnosed
- ejection fraction
- prognostic factors
- peritoneal dialysis
- smoking cessation
- machine learning
- cell therapy
- deep learning
- artificial intelligence